Great potential of miRNAs as predictive and prognostic markers for cancer

References

• Cho WC. Molecular diagnostics for monitoring and predicting therapeutic effect in cancer. Expert Rev. Mol. Diagn.11(1), 9–12 (2011).
   PubMed Web of Science ®Google Scholar
• Ranade AR, Cherba D, Sridhar S et al. MicroRNA 92a-2*: a biomarker predictive for chemoresistance and prognostic for survival in patients with small cell lung cancer. J. Thorac. Oncol.5(8), 1273–1278 (2010).
   PubMed Web of Science ®Google Scholar
• Ohuchida K, Mizumoto K, Kayashima T et al. MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer. Ann. Surg. Oncol.18(8), 2381–2387 (2011).
   PubMed Web of Science ®Google Scholar
• Leskelä S, Leandro-García LJ, Mendiola M et al. The miR-200 family controls β-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr. Relat. Cancer18(1), 85–95 (2010).
   PubMed Web of Science ®Google Scholar
• Rothé F, Ignatiadis M, Chaboteaux C et al. Global microRNA expression profiling identifies miR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS One6(6), e20980 (2011).
   PubMed Web of Science ®Google Scholar
• Tan X, Qin W, Zhang L et al. A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Clin. Cancer Res.17(21), 6802–6811 (2011).
   PubMed Web of Science ®Google Scholar
• Zhang T, Wang Q, Zhao D et al. The oncogenetic role of microRNA-31 as a potential biomarker in oesophageal squamous cell carcinoma. Clin. Sci. (Lond.)121(10), 437–447 (2011).
   PubMed Web of Science ®Google Scholar
• Jamieson NB, Morran DC, Morton JP et al. MicroRNA molecular profiles associated with diagnosis, clinicopathological criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clin. Cancer Res.18(2), 534–545 (2012).
   PubMed Web of Science ®Google Scholar
• Long Q, Johnson BA, Osunkoya AO et al. Protein-coding and microRNA biomarkers of recurrence of prostate cancer following radical prostatectomy. Am. J. Pathol.179(1), 46–54 (2011).
   PubMed Web of Science ®Google Scholar
• Alencar AJ, Malumbres R, Kozloski GA et al. MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Clin. Cancer Res.17(12), 4125–4135 (2011).
   PubMed Web of Science ®Google Scholar
• Yip L, Kelly L, Shuai Y et al. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann. Surg. Oncol.18(7), 2035–2041 (2011).
   PubMed Web of Science ®Google Scholar
• Kogo R, Mimori K, Tanaka F, Komune S, Mori M. Clinical significance of miR-146a in gastric cancer cases. Clin. Cancer Res.17(13), 4277–4284 (2011).
   PubMed Web of Science ®Google Scholar
• Heegaard NH, Schetter AJ, Welsh JA, Yoneda M, Bowman ED, Harris CC. Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int. J. Cancer130(6), 1378–1386 (2012).
   PubMed Web of Science ®Google Scholar
• Zuo Z, Calin GA, de Paula HM et al. Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome. Blood118(2), 413–415 (2011).
   PubMed Web of Science ®Google Scholar
• Liu N, Chen NY, Cui RX et al. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol. (2012) (In Press).
   Google Scholar
• Vickers MM, Bar J, Gorn-Hondermann I et al. Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease. Clin. Exp. Metastasis29(2), 123–132 (2012).
   PubMed Web of Science ®Google Scholar
• Costa FF, Bischof JM, Vanin EF et al. Identification of microRNAs as potential prognostic markers in ependymoma. PLoS One6(10), e25114 (2011).
   Google Scholar
• Qian P, Zuo Z, Wu Z et al. Pivotal role of reduced let-7g expression in breast cancer invasion and metastasis. Cancer Res.71(20), 6463–6474 (2011).
   PubMed Web of Science ®Google Scholar
• Buffa FM, Camps C, Winchester L et al. microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res.71(17), 5635–5645 (2011).
   PubMed Web of Science ®Google Scholar
• Xiong Y, Li Z, Ji M et al. miR-29b regulates expression of MLLT11 (AF1Q), an MLL fusion partner, and low miR-29b expression associates with adverse cytogenetics and poor overall survival in AML. Br. J. Haematol.153(6), 753–757 (2011).
   PubMed Web of Science ®Google Scholar
• Abraham D, Jackson N, Gundara JS et al. MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets. Clin. Cancer Res.17(14), 4772–4781 (2011).
   PubMed Web of Science ®Google Scholar
• Cho WC. Circulating microRNAs as minimally invasive biomarkers for cancer theragnosis and prognosis. Front. Genet.2(7), 1–6 (2011).
   PubMedGoogle Scholar
• Cho WC. Epigenetic alteration of microRNAs in feces of colorectal cancer and its clinical significance. Expert Rev. Mol. Diagn.11(7), 691–694 (2011).
   PubMed Web of Science ®Google Scholar
• Kalimutho M, Di Cecilla S, Del Vecchio Blanco G et al. Epigenetically silenced miR-34b/c as a novel faecal-based screening marker for colorectal cancer. Br. J. Cancer104(11), 1770–1778 (2011).
   PubMed Web of Science ®Google Scholar
• Cho WC. Promises and challenges in developing miRNA as a molecular diagnostic tool for lung cancer. Expert Rev. Mol. Diagn.11(8), 763–766 (2011).
   PubMed Web of Science ®Google Scholar